Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. Its lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, and insulin lispro; antidiabetic drugs; and oral hypoglycemic drugs, as well as Gan Shulin pens, blood glucose meters, and other medical devices. It offers building materials. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.

Mr. Junyu  Chi

Chief Accountant

Mr. Zhiqiang  Du

Deputy General Manager

Ms. Fan  Su

Deputy GM & Board Secretary

Mr. Guodong  Zhang

Deputy GM & Director

Mr. Sheng Leng  Chun

Chairman & GM

Mr. Hong  Chen

Chief Engineer and Deputy General Manager

Mr. Wenhai  Zhang

Nome da empresa	Capitalização de mercado
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Bristol-Myers Squibb Company	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M
Novartis AG	0M

Tonghua Dongbao Pharmaceutical Co., Ltd.

Tonghua Dongbao Pharmaceutical Co., Ltd. Lista de concorrentes

Principais concorrentes